Allison Rosenthal has joined Lykos Therapeutics as the company’s first Chief Commercial Officer. Ms. Rosenthal leads Lykos’ trailblazing commercial strategy and operations, initially focusing on the potential launch of MDMA-assisted therapy for their lead program to treat those suffering with PTSD. If approved by the FDA, anticipated in Q3 of 2024, this will be the first psychedelic-assisted therapy approved for medical use.

Learn more about Allison and her role here.